Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
RHHVF Quote, Financials, Valuation and Earnings
Last price:
$407.99
Seasonality move
:
0.6%
Day range:
$407.99 - $422.62
52-week range:
$269.80 - $424.40
Dividend yield:
2.62%
P/E ratio:
30.85x
P/S ratio:
4.74x
P/B ratio:
6.80x
Volume:
12.6K
Avg. volume:
14.4K
1-year change:
50.57%
Market cap:
$333.9B
Revenue:
$68.7B
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
$18.7B | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
$419.27 | -- | $333.9B | 30.85x | $11.00 | 2.62% | 4.74x |
|
ACIU
AC Immune SA
|
$3.12 | $9.01 | $313.9M | -- | $0.00 | 0% | 60.84x |
|
ADXN
Addex Therapeutics Ltd.
|
$8.89 | $30.00 | $11M | 0.77x | $0.00 | 0% | 40.66x |
|
CRSP
CRISPR Therapeutics AG
|
$56.71 | $81.33 | $5.4B | -- | $0.00 | 0% | 129.35x |
|
ONC
BeOne Medicines Ltd.
|
$312.32 | $400.06 | $34.6B | 600.96x | $0.00 | 0% | 6.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
53.53% | -0.150 | -- | 0.88x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RHHVF
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Roche Holding AG vs. Competitors
-
Which has Higher Returns RHHVF or ACIU?
AC Immune SA has a net margin of -- compared to Roche Holding AG's net margin of -1688.87%. Roche Holding AG's return on equity of 28.65% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About RHHVF or ACIU?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 186.4%. Given that AC Immune SA has higher upside potential than Roche Holding AG, analysts believe AC Immune SA is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 ACIUAC Immune SA4 0 0 -
Is RHHVF or ACIU More Risky?
Roche Holding AG has a beta of 0.465, which suggesting that the stock is 53.518% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock RHHVF or ACIU?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.62%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 93.4% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or ACIU?
Roche Holding AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Roche Holding AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Roche Holding AG's price-to-earnings ratio is 30.85x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.74x versus 60.84x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.74x 30.85x -- -- ACIUAC Immune SA60.84x -- $1.2M -$19.8M
-
Which has Higher Returns RHHVF or ADXN?
Addex Therapeutics Ltd. has a net margin of -- compared to Roche Holding AG's net margin of -3178.71%. Roche Holding AG's return on equity of 28.65% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About RHHVF or ADXN?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 258%. Given that Addex Therapeutics Ltd. has higher upside potential than Roche Holding AG, analysts believe Addex Therapeutics Ltd. is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is RHHVF or ADXN More Risky?
Roche Holding AG has a beta of 0.465, which suggesting that the stock is 53.518% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock RHHVF or ADXN?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.62%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 93.4% of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or ADXN?
Roche Holding AG quarterly revenues are --, which are smaller than Addex Therapeutics Ltd. quarterly revenues of $62K. Roche Holding AG's net income of -- is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, Roche Holding AG's price-to-earnings ratio is 30.85x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.74x versus 40.66x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.74x 30.85x -- -- ADXNAddex Therapeutics Ltd.40.66x 0.77x $62K -$2M
-
Which has Higher Returns RHHVF or CRSP?
CRISPR Therapeutics AG has a net margin of -- compared to Roche Holding AG's net margin of -11973.12%. Roche Holding AG's return on equity of 28.65% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About RHHVF or CRSP?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 43.42%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is RHHVF or CRSP More Risky?
Roche Holding AG has a beta of 0.465, which suggesting that the stock is 53.518% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock RHHVF or CRSP?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.62%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 93.4% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or CRSP?
Roche Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Roche Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Roche Holding AG's price-to-earnings ratio is 30.85x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.74x versus 129.35x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.74x 30.85x -- -- CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M
-
Which has Higher Returns RHHVF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Roche Holding AG's net margin of 8.84%. Roche Holding AG's return on equity of 28.65% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital RHHVFRoche Holding AG-- -- $82.8B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About RHHVF or ONC?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.09%. Given that BeOne Medicines Ltd. has higher upside potential than Roche Holding AG, analysts believe BeOne Medicines Ltd. is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHVFRoche Holding AG0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is RHHVF or ONC More Risky?
Roche Holding AG has a beta of 0.465, which suggesting that the stock is 53.518% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock RHHVF or ONC?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.62%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 93.4% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHVF or ONC?
Roche Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Roche Holding AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Roche Holding AG's price-to-earnings ratio is 30.85x while BeOne Medicines Ltd.'s PE ratio is 600.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.74x versus 6.98x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHVFRoche Holding AG4.74x 30.85x -- -- ONCBeOne Medicines Ltd.6.98x 600.96x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
